Walleye Trading’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.75M | Sell |
7,700
-52,700
| -87% | -$9.38M | ﹤0.01% | 1943 |
|
|
2026
Q1 | $10.4M | Buy |
60,400
+59,700
| +8,529% | +$11.1M | 0.02% | 770 |
|
|
2025
Q4 | $140K | Sell |
700
-5,600
| -89% | -$1.02M | ﹤0.01% | 3573 |
|
|
2025
Q3 | $986K | Buy |
6,300
+5,300
| +530% | +$842K | ﹤0.01% | 2283 |
|
|
2025
Q2 | $152K | Sell |
1,000
-1,800
| -64% | -$240K | ﹤0.01% | 3395 |
|
|
2025
Q1 | $421K | Sell |
2,800
-400
| -13% | -$67.1K | ﹤0.01% | 2630 |
|
|
2024
Q4 | $591K | Buy |
3,200
+1,000
| +45% | +$193K | ﹤0.01% | 2511 |
|
|
2024
Q3 | $433K | Sell |
2,200
-600
| -21% | -$125K | ﹤0.01% | 2607 |
|
|
2024
Q2 | $578K | Sell |
2,800
-30,100
| -91% | -$6.82M | ﹤0.01% | 2408 |
|
|
2024
Q1 | $8.91M | Buy |
32,900
+700
| +2% | +$167K | 0.02% | 787 |
|
|
2023
Q4 | $7.61M | Sell |
32,200
-7,700
| -19% | -$1.51M | 0.02% | 946 |
|
|
2023
Q3 | $7.82M | Buy |
39,900
+21,200
| +113% | +$4.35M | 0.02% | 816 |
|
|
2023
Q2 | $3.93M | Buy |
18,700
+10,000
| +115% | +$1.99M | 0.01% | 1138 |
|
|
2023
Q1 | $1.76M | Buy |
8,700
+5,300
| +156% | +$1.2M | ﹤0.01% | 1780 |
|
|
2022
Q4 | $741K | Buy |
3,400
+3,000
| +750% | +$655K | ﹤0.01% | 2485 |
|
|
2022
Q3 | $79K | Buy |
+400
| New | +$86.4K | ﹤0.01% | 4129 |
|
|
2022
Q1 | – | Sell |
-700
| Closed | -$264K | – | 5406 |
|
|
2021
Q4 | $264K | Hold |
700
| – | – | ﹤0.01% | 3614 |
|
|
2021
Q3 | $289K | Sell |
700
-2,200
| -76% | -$914K | ﹤0.01% | 3489 |
|
|
2021
Q2 | $1.07M | Buy |
2,900
+400
| +16% | +$134K | ﹤0.01% | 2068 |
|
|
2021
Q1 | $725K | Sell |
2,500
-300
| -11% | -$83.4K | ﹤0.01% | 2247 |
|
|
2020
Q4 | $700K | Buy |
2,800
+1,100
| +65% | +$262K | ﹤0.01% | 2360 |
|
|
2020
Q3 | $385K | Buy |
1,700
+1,200
| +240% | +$249K | ﹤0.01% | 2473 |
|
|
2020
Q2 | $87K | Buy |
500
+200
| +67% | +$31.9K | ﹤0.01% | 3580 |
|
|
2020
Q1 | $38K | Sell |
300
-500
| -63% | -$75K | ﹤0.01% | 3496 |
|
|
2019
Q4 | $122K | Buy |
800
+500
| +167% | +$69.2K | ﹤0.01% | 3460 |
|
|
2019
Q3 | $40K | Buy |
300
+100
| +50% | +$13.4K | ﹤0.01% | 3630 |
|
|
2019
Q2 | $28K | Buy |
200
+100
| +100% | +$13.6K | ﹤0.01% | 3682 |
|
|
2019
Q1 | $15K | Sell |
100
-2,100
| -95% | -$276K | ﹤0.01% | 3943 |
|
|
2018
Q4 | $249K | Sell |
2,200
-3,400
| -61% | -$426K | ﹤0.01% | 3182 |
|
|
2018
Q3 | $753K | Buy |
+5,600
| New | +$691K | ﹤0.01% | 2420 |
|
Other funds holding CRL
AI
Walleye Trading's CRL Position: Q2 2026 in Review
Walleye Trading reduced its Charles River Laboratories (CRL) stake by 92% in Q2 2026, selling an estimated $5.19M and leaving 2,511 shares worth $569K. The position accounts for ﹤0.01% of the portfolio, ranked #2615.
Walleye Trading first reported a position in CRL in Q3 2014 and has held it in 20 quarters since. The position peaked at $5.46M in Q1 2026. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Walleye Trading held 2,511 shares of Charles River Laboratories worth $569K as of Q2 2026.
- Walleye Trading sold 29,150 Charles River Laboratories shares in Q2 2026, an estimated $5.19M.
- Charles River Laboratories made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #2615 holding.
- Walleye Trading first reported a position in Charles River Laboratories in Q3 2014 and has held it in 20 quarters since.
- Walleye Trading's Charles River Laboratories position peaked at $5.46M in Q1 2026.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.